Vigil Neuroscience Secures Positive Opinion From European Medicines Agency On Orphan Drug Designation For VGL101 For Treatment Of ALSP
Portfolio Pulse from Benzinga Newsdesk
Vigil Neuroscience has received a positive opinion from the European Medicines Agency on the orphan drug designation for VGL101, a treatment for ALSP. The company is currently evaluating VGL101 in a Phase 2 proof-of-concept trial. The drug was previously granted orphan drug designation by the U.S. FDA in July 2022.
September 26, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vigil Neuroscience's VGL101 has received a positive opinion from the European Medicines Agency, which could potentially open up a new market for the drug. This news follows the drug's orphan designation by the U.S. FDA in July 2022.
The positive opinion from the European Medicines Agency is a significant step towards the approval of VGL101 in Europe. This could potentially open up a new market for the drug, which would be beneficial for Vigil Neuroscience. The previous orphan drug designation by the U.S. FDA also adds to the credibility of the drug, which could positively impact the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100